Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups
07 juin 2022 07h00 HE
|
Skye Bioscience, Inc.
New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system San Diego, California, June 07, 2022 (GLOBE...
Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics
12 mai 2022 09h05 HE
|
Skye Bioscience, Inc.
Arrangement is expected to fund Skye’s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022 ...
Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal
05 mai 2022 07h00 HE
|
Skye Bioscience, Inc.
San Diego, California, May 05, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid...
Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
28 avr. 2022 07h00 HE
|
Skye Bioscience, Inc.
San Diego, California, April 28, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid...
Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
03 mars 2022 08h30 HE
|
Skye Bioscience, Inc.
San Diego, Calif, March 03, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
16 févr. 2022 08h30 HE
|
Skye Bioscience, Inc.
Initiation of Phase 1 clinical trial of SBI-100 ophthalmic nanoemulsion expected in the second quarter of 2022 SAN DIEGO, CA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB:...
Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
01 févr. 2022 08h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022
10 janv. 2022 07h00 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a pharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat...
Skye Bioscience to Present at H.C. Wainwright BIOCONNECT Virtual Conference
04 janv. 2022 08h30 HE
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat...
Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD
15 déc. 2021 08h30 HE
|
Skye Bioscience, Inc.
Skye Bioscience Announces Promotion of Tu Diep, MSc to Chief Development Officer SAN DIEGO, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the...